Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy, Durability, Safety, and Tolerability of RP-G28 in Patients With Lactose Intolerance

NCT03597516 is registered in ClinicalTrials.gov with Ritter Pharmaceuticals, Inc. as lead sponsor.

NCT NCT03597516
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03597516 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy, Durability, Safety, and Tolerability of RP-G28 in Patients With Lactose Intolerance
Lead sponsor
Ritter Pharmaceuticals, Inc.
Phase
Phase 3
Overall status
Completed
Start date
June 26, 2018
Completion date
July 2, 2019
Enrollment
557 (actual)
Sites
35

Conditions

As the registry lists them; a condition with its own page is linked.

lactose intolerance